STOCK TITAN

ARTV Insider Notice: 25,500 Common Shares from RSUs Listed for Sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Artiva Biotherapeutics reported a Form 144 notice showing a planned sale of 25,500 common shares held as Restricted Stock Units that were acquired and are to be sold on 08/15/2025. The broker listed is Morgan Stanley Smith Barney LLC and the planned transaction lists an aggregate market value of $68,850 based on 25,500 shares. The filing records 24,425,762 shares outstanding and identifies NASDAQ as the exchange. The filer reports no securities sold in the prior three months and includes the standard representation that the selling person does not possess undisclosed material adverse information.

The notice appears routine: shares arose from company RSUs, the sale is executed through a major broker, and there are no prior sales reported in the three-month lookback period.

Positive

  • Transaction is clearly documented with acquisition date, nature (RSUs), broker, and sale date provided
  • No prior sales in the past three months, suggesting this is a scheduled disposition rather than frequent insider trading
  • Sale size is small relative to shares outstanding (~0.10%), limiting immediate dilutive impact

Negative

  • None.

Insights

TL;DR Routine insider sale of RSU shares through a broker; modest size relative to outstanding shares.

The filing documents a proposed sale of 25,500 shares from Restricted Stock Units, with an aggregate market value of $68,850. Compared with 24.4 million shares outstanding, the sale is immaterial in dilution terms (~0.10% of outstanding shares). The use of a major broker and the absence of sales in the prior three months point to a scheduled, non-urgent disposition rather than an emergency liquidity event. For investors, this is a routine insider liquidity action with limited direct impact on capitalization or control.

TL;DR Form 144 conforms to Rule 144 reporting requirements; no red flags in the notice.

The notice indicates shares were acquired and paid on the same date (RSU vesting on 08/15/2025) and that the seller affirms no material nonpublic information. The filing shows "Nothing to Report" for sales in the prior three months and specifies the broker and NASDAQ as venue. From a compliance perspective, the form contains the expected elements: acquisition details, amount, broker, and certifications. There is no indication of irregular transaction structure or contingent payment arrangements.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What is Artiva Biotherapeutics (ARTV) selling according to the Form 144?

The filer plans to sell 25,500 common shares that were acquired as Restricted Stock Units, with the sale dated 08/15/2025.

Through which broker will the ARTV shares be sold?

The filing lists Morgan Stanley Smith Barney LLC as the broker handling the proposed sale.

What is the aggregate market value and how many shares are outstanding?

The aggregate market value is listed as $68,850 and the number of shares outstanding is 24,425,762.

Has the filer sold any Artiva securities in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Does the filer assert possession of material nonpublic information?

No. The filer represents by signature that they do not know any material adverse information about the issuer that is not publicly disclosed.
ARTIVA BIOTHERAPEUTICS INC

NASDAQ:ARTV

ARTV Rankings

ARTV Latest News

ARTV Latest SEC Filings

ARTV Stock Data

101.86M
17.50M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SAN DIEGO